Akiram Therapeutics to Present First Clinical Results from AKIR001 at EANM 2026
Swedish biotech firm Akiram Therapeutics will present initial clinical data from its AKIR001 drug candidate's Phase I trial at the EANM 2026 Congress in Vienna. Preliminary findings show a favorable safety profile and tumor retention.
Swedish clinical-stage biotechnology company Akiram Therapeutics announced that the first clinical data from the ongoing Phase I trial of its lead drug candidate, [177]Lu-AKIR001, will be presented at the EANM 2026 Congress in Vienna, taking place October 17–21. The study aims to evaluate the safety and preliminary efficacy of the therapeutic.
Preliminary results from the trial indicate a favorable safety profile within the investigated activity range. The data also demonstrated sustained tumor retention, supporting further dose escalation and clinical evaluation of AKIR001.
Akiram Therapeutics specializes in molecular radiotherapy, developing targeted treatments for cancer. The company is advancing its pipeline of radiopharmaceutical candidates through clinical development.
The EANM Congress is a significant event for the nuclear medicine and medical imaging community, serving as a venue for presenting research findings.